Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations
Over the past decades, the role of rearranged during transfection (RET) alterations in tumorigenesis has been firmly established. RET kinase inhibition is an essential therapeutic target in patients with RET-altered cancers. In clinical practice, initial efficacy can be achieved in patients through the utilization of multikinase inhibitors (MKIs) with RET inhibitory activity. However, the effectiveness of these MKIs is impeded by the adverse events associated with off-target effects. Recently, many RET-selective inhibitors, characterized by heightened specificity and potency, have been developed, representing a substantial breakthrough in the field of RET precision oncology. This Perspective focuses on the contemporary understanding of RET mutations, recent advancements in next-generation RET inhibitors, and the challenges associated with resistance to RET inhibitors. It provides valuable insights for the development of next-generation MKIs and selective RET inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Journal of medicinal chemistry - 67(2024), 6 vom: 28. März, Seite 4346-4375 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Zi-Xuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 2.7.10.1 |
|---|
| Anmerkungen: |
Date Completed 29.03.2024 Date Revised 29.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acs.jmedchem.3c02319 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369738152 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369738152 | ||
| 003 | DE-627 | ||
| 005 | 20240330001257.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.jmedchem.3c02319 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM369738152 | ||
| 035 | |a (NLM)38484122 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Zi-Xuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Over the past decades, the role of rearranged during transfection (RET) alterations in tumorigenesis has been firmly established. RET kinase inhibition is an essential therapeutic target in patients with RET-altered cancers. In clinical practice, initial efficacy can be achieved in patients through the utilization of multikinase inhibitors (MKIs) with RET inhibitory activity. However, the effectiveness of these MKIs is impeded by the adverse events associated with off-target effects. Recently, many RET-selective inhibitors, characterized by heightened specificity and potency, have been developed, representing a substantial breakthrough in the field of RET precision oncology. This Perspective focuses on the contemporary understanding of RET mutations, recent advancements in next-generation RET inhibitors, and the challenges associated with resistance to RET inhibitors. It provides valuable insights for the development of next-generation MKIs and selective RET inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Proto-Oncogene Proteins c-ret |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a RET protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Li, Qing-Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Jiao |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jia-Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jing-Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Meng-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qing-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Zhen-Jiang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Tian-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Wei-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Leng, Xue-Jiao |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Shan-Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Yan-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Nian-Guang |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Zhi-Hao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medicinal chemistry |d 1963 |g 67(2024), 6 vom: 28. März, Seite 4346-4375 |w (DE-627)NLM000006602 |x 1520-4804 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2024 |g number:6 |g day:28 |g month:03 |g pages:4346-4375 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.jmedchem.3c02319 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2024 |e 6 |b 28 |c 03 |h 4346-4375 | ||